BiotechBistro Forums Tag: biotechnology

BiotechBistro Forums Tag: biotechnology http://biotechbistro.com/forum/tags/biotechnology The Business of Biotechnology en-US Mon, 06 Feb 2012 09:44:11 +0000 bbpress 1.0-alpha-4 <![CDATA[Search]]> q http://biotechbistro.com/forum/search.php cgorsky on "Abzyme Therapeutics Licenses SUMOpro from LifeSensors" http://biotechbistro.com/forum/topic/abzyme-therapeutics-licenses-sumopro-from-lifesensors#post-247 Thu, 03 Nov 2011 11:34:07 +0000 cgorsky 247@http://biotechbistro.com/forum/ Abzyme Therapeutics, LLC was founded to develop human therapeutic monoclonal antibodies. They have licensed LifeSensors protein expression platform, SUMOpro™ to further their monoclonal antibody production. MALVERN, PA -- November 3, 2011 -- Abzyme Therapeutics, a new biotechnology company dedicated to developing methods to generate human monoclonal antibodies for the treatment of disease, announced today that they have entered into an exclusive agreement with LifeSensors to license their proprietary protein expression platform, SUMOpro™. Enhanced protein expression is key to the evolution and development of antibodies and the LifeSensors SUMOpro™ technology is a protein expression platform that can dramatically enhance overall protein production through increased protein translation, solubility, and stability. “The use of Abzyme Therapeutics’ systems and platforms will allow monoclonal antibodies to be used for the treatment of Alzheimer’s disease, cancer, autoimmune disease, and infectious diseases” said Dr. Tauseef Butt, co-founder and Chair of Abzyme Therapeutics Board of Directors. Abzyme is currently focused on treating Alzheimer’s by developing proteolytic antibodies capable of hydrolyzing and clearing beta-amyloids from the human blood stream. These antibodies are designed to hydrolyze multiple antigen target molecules and overcome the problem of resistance, providing increased benefit at reduced doses. Alternatively, the generation irreversibly and repeatedly of these antibodies in the future will be critical in the development of treatments for cancers and other diseases. Abzyme Therapeutics, LLC has established its headquarters in the Great Valley Technology Center, Malvern, PA and aims to exploit their platforms for the development of novel therapeutic antibodies that will offer affordable medicines with increased benefit, requiring reduced dosages. With therapeutic antibody evolution platforms based on intracellular (iHUMab)/extracellular (eHuMab) genetic selection systems, Abzyme Therapeutics is capable of generating highly diversified human antibody repertoires. For more information please visit <a href="http://www.abzymetx.com" rel="nofollow">http://www.abzymetx.com</a>. LifeSensors, Inc. is the leading producer of innovative research tools for the ubiquitin and ubiquitin-like protein pathways. Its prokaryotic and eukaryotic protein expression platforms SUMOpro™ and SUMOstar™ are used worldwide to overcome bottlenecks in protein production. LifeSensors’ technologies enable research once difficult to achieve by using a wide variety of high quality tools including enzymes, substrates, and inhibitors. For more information please visit <a href="http://www.lifesensors.com" rel="nofollow">http://www.lifesensors.com</a>. Contact: LifeSensors, Inc. Email: <a href="mailto:info@lifesensors.com">info@lifesensors.com</a> Phone: (610) 644-8845 <a href="http://www.lifesensors.com" rel="nofollow">http://www.lifesensors.com</a> Or Abzyme Therapeutics, LLC Dr. Hiep Tran, Chief Scientific Officer Email: <a href="mailto:info@abzymetx.com">info@abzymetx.com</a> Phone (610) 990-7531 williams_john on "Lifeline Skin Care Video" http://biotechbistro.com/forum/topic/lifeline-skin-care-video#post-242 Fri, 28 Oct 2011 01:26:32 +0000 williams_john 242@http://biotechbistro.com/forum/ I have also hear about "International Stem Cell" which now a day go a lot of work for humans....Discover lot of treatment for skin care, and eye care also.... Also introduce good brands for treatment..... chelsea.scorr on "Online Business Applications Launches IRMS Mobile Application" http://biotechbistro.com/forum/topic/online-business-applications-launches-irms-mobile-application#post-239 Wed, 26 Oct 2011 08:05:26 +0000 chelsea.scorr 239@http://biotechbistro.com/forum/ CONTACT: Joe Pierce Vice President of Sales and Marketing Online Business Applications (630) 243-9810 ext. 209 <a href="mailto:sales@irmsonline.com">sales@irmsonline.com</a> Online Business Applications Launches IRMS Mobile Application (Woodridge, IL; October 26, 2011) – Online Business Applications (OBA), a leader in the health science software industry that offers advanced solutions for pharmaceutical, biotechnology and medical device companies in the areas of medical communications and drug safety, has released its mobile request application, IRMS Mobile, for iPad, iPhone and other mobile devices. This efficient application enables a company’s field force to easily enter and submit medical information requests from physicians with a convenient mobile device. IRMS Mobile sends the request to the company’s IRMS (Information Request Management System) call center where it is routed to a medical information professional for fulfillment. The field sales representative or science liaison also may track the information requested and receive automatic notifications of successful receipt and completion of the request. “This is a great way to easily collect a physician’s signature to verify an unsolicited request and provide a timely response, ultimately allowing more opportunities for written prescriptions and higher sales,” said Joe Pierce, OBA vice president of sales and marketing. “The seamless integration of our server-based IRMS software, the world’s leading medical information system, with our mobile application allows field representatives to use the technology to its fullest. Both IRMS and IRMS Mobile are so versatile that they can easily link information from other software systems and use that information to process a request.” IRMS Mobile can be installed on the company’s servers where the data is stored in the company’s database or it can be hosted by OBA as a Web-based cloud service with no installation. IRMS is 21 CFR Part 11 compliant and has been fully validated. To learn more, contact Reed McLaughlin, account manager, at (630) 243-9810 ext. 225 or <a href="mailto:reed.mclaughlin@irmsonline.com">reed.mclaughlin@irmsonline.com</a>. OBA has provided advanced software solutions for the pharmaceutical, biotechnology and medical device industries in the areas of medical communications and drug safety for over 25 years. The IRMS software offers enhanced tools, including automated letter generation, flexible ad-hoc query capability with built-in custom reporting, and document and correspondence management. In addition, IRMS offers optional adverse event, quality assurance, product complaint and content management functionality. About Online Business Applications For over 25 years, Online Business Applications (OBA) has been committed to providing advanced software solutions for the pharmaceutical, biotechnology and medical device industries in the areas of medical communications and drug safety. Partnered with over 100 pharmaceutical and biotech companies in over 70 countries, OBA’s IRMS (Information Request Management System), the world’s leading medical information system, offers enhanced tools, including built-in custom reporting, document and correspondence management, FAQ database and built-in data and privacy protection. IRMS is designed to be 21 CFR Part 11 compliant and has been fully validated. For more information, visit <a href="http://www.irmsonline.com" rel="nofollow">http://www.irmsonline.com</a>. ### pjbosc on "Lifeline Skin Care Video" http://biotechbistro.com/forum/topic/lifeline-skin-care-video#post-213 Thu, 22 Sep 2011 14:54:11 +0000 pjbosc 213@http://biotechbistro.com/forum/ Watch video here - <a href="http://bit.ly/o7MRvz" rel="nofollow">http://bit.ly/o7MRvz</a> Lifeline Skin Care® (Lifeline) is a wholly owned subsidiary of International Stem Cell Corporation (OTCBB:ISCO), a publicly traded biotechnology company which has developed a powerful and ethical new stem cell technology called “parthenogenesis”. ISCO created Lifeline Skin Care® to further develop its discoveries that extracts from human parthenogenetic stem cells had beneficial effects on human skin cells. International Stem Cell is focused on advancing its human parthenogenetic stem cell technology towards finding treatments for blinding diseases of the eye, liver disease, diseases of the nervous system and diabetes. Our goal at Lifeline Skin Care® is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology and skin cream formulation technology to create the highest quality, scientifically tested and most effective skin care products. ASHG Human Genetics Society on "American Society of Human Genetics Hosts 12th Int'l. Congress of Human Genetics" http://biotechbistro.com/forum/topic/american-society-of-human-genetics-hosts-12th-intl-congress-of-human-genetics#post-198 Tue, 30 Aug 2011 14:26:05 +0000 ASHG Human Genetics Society 198@http://biotechbistro.com/forum/ Media Contact: Kristen Long <a href="mailto:klong@ashg.org">klong@ashg.org</a> 301-634-7346 AMERICAN SOCIETY OF HUMAN GENETICS TO HOST 12TH INTERNATIONAL CONGRESS OF HUMAN GENETICS IN MONTREAL World's top genetic scientists to present latest research findings at ICHG/ASHG 2011 Meeting, on October 11-15, in Montreal, Canada BETHESDA, MD – August 30, 2011 – The world's top scientists and clinicians in the human genetics field will gather to present their latest research findings at the 12th International Congress of Human Genetics (ICHG) / 61st Annual Meeting of the American Society of Human Genetics (ASHG), which will be held on October 11-15, 2011, in Montreal (Quebec), Canada, at the Montreal Convention Center. Founded in 1948, the American Society of Human Genetics (ASHG) is the primary professional membership organization for human genetics specialists worldwide, representing nearly 8,000 researchers, academicians, clinicians, genetic counselors, nurses and others with a special interest in this area. The Society's Annual Meeting is the world's largest gathering of human genetics professionals and a forum for renowned experts in the field to share their latest research results. The International Congress of Human Genetics (ICHG), which is sponsored by ASHG in partnership with the International Federation of Human Genetics Societies (IFHGS), is the foremost meeting of the worldwide human genetics community and is held every five years. In 2011, the 12th ICHG Meeting will be the major focal point and platform for the world's most exciting research, and attendance at this year's meeting is anticipated to be more than 7,000 delegates from over 60 countries around the world. With more than 300 platform and plenary presentations, 3,500 posters, 24 invited sessions, special symposia and panel debate sessions, as well as onsite press briefing events that will be webcast to the media, the ICHG/ASHG 2011 Meeting will provide journalists with information on the most important and recent developments in human genetics and genomics research. In addition, nearly 250 U.S. and international exhibitors will offer an unprecedented opportunity to view the latest advances in cutting-edge genetics products, services, and technology, many of which have been derived from work presented at previous ASHG meetings. PRESS BRIEFING EVENTS & WEBCASTS: ASHG will be hosting several press briefing events onsite in the Montreal Convention Center during the week of the ICHG/ASHG 2011 Meeting. The Society will also be webcasting this year's press briefings to allow credentialed members of the media who are unable to attend the meeting in-person to view the webcasts online. If you cannot attend the ICHG/ASHG 2011 Meeting in Montreal this October, but still wish to receive embargoed press releases from ASHG and/or register to view online webcasts of the Society's press briefing events, please e-mail your request to Kristen Long at <a href="mailto:klong@ashg.org">klong@ashg.org</a>, and include your press affiliation, title, and contact information. The scientific sessions and press briefings at the ICHG/ASHG 2011 Meeting will feature presentations from prominent experts in the field on a diverse range of the latest topics of interest in human genetics and genomics, including the following: •1000 Genomes Project •Biotechnology •Cancer Genetics •Clinical & Medical Genetics / Translational Research •Ethical, Legal, Social, & Policy Issues •Epigenetics & Genomics •Evolution & Population Genetics •Family Health History •Gene Therapy & Genetic Disease Treatments •Gene Patenting •Genetic Testing •Common & Rare Disease Genetics •Genome Architecture (CNVs & Structural Variation) •Genome Sequencing & Genome-Wide Association Studies (GWAS) •Neurogenetics & Psychiatric Genetics •Pharmacogenetics (Drug Response & Dosage) •Personalized Medicine •Public Health Genomics & Education Initiatives •Stem Cell Research To view the schedule of events and scientific sessions, please visit the ICHG 2011 Meeting Web site at: <a href="http://www.ichg2011.org/pages/scheduleofevents.shtml" rel="nofollow">http://www.ichg2011.org/pages/scheduleofevents.shtml</a>. For general information about the ICHG/ASHG 2011 Meeting program, speakers, and the full schedule of events, visit: <a href="http://www.ichg2011.org" rel="nofollow">http://www.ichg2011.org</a>. PRESS REGISTRATION INFORMATION & GUIDELINES: The ICHG/ASHG 2011 Meeting is open to print, online and broadcast news media, as well as health, medical and science reporters, and freelance writers on a verifiable assignment from an established news source. Complimentary meeting registration will be available to members of the media who provide appropriate press credentials and identification. ASHG offers reporters many resources onsite at the meeting, including news releases, press conferences, media interviews with top experts in the field, and a press room with free Internet access and complimentary refreshments. To pre-register to attend the ICHG/ASHG 2011 Meeting as a member of the press, please complete the online press registration application form by October 1, 2011: <a href="http://www.ichg2011.org/pages/press_register.shtml" rel="nofollow">http://www.ichg2011.org/pages/press_register.shtml</a>. Press attendees are strongly encouraged to register online for the meeting in advance, however, credentialed members of the press* can register onsite at the ICHG/ASHG Press Office as well (located in Room 518B, on the fifth floor of the Montreal Convention Center). For more information about ASHG's press policies and guidelines, press registration procedures, as well as details about this year's press briefing sessions, webcasts, speakers, and experts available for interview at the 2011 Meeting, go to: <a href="http://www.ichg2011.org/pages/press.shtml" rel="nofollow">http://www.ichg2011.org/pages/press.shtml</a>. ICHG/ASHG 2011 SOCIAL MEDIA: Follow ICHG/ASHG 2011 Meeting posts on Twitter using the hashtag: #ICHG2011. Be sure to follow the #ICHG2011 hashtag during the week of the meeting to get the inside scoop on the latest genetics research findings presented at the conference from the many attendees who will be tweeting live at the scientific sessions. Also, follow ASHG on Twitter (@GeneticsSociety), Facebook, LinkedIn, and YouTube to get the latest 2011 Meeting updates and news tips both before and during the week of the conference. ABOUT THE AMERICAN SOCIETY OF HUMAN GENETICS Founded in 1948, the American Society of Human Genetics (ASHG) is the primary professional membership organization for human genetics specialists worldwide. The nearly 8,000 members of ASHG include researchers, academicians, clinicians, laboratory practice professionals, genetic counselors, nurses and others with a special interest in human genetics. The Society's mission is to serve research scientists, health professionals and the public by providing forums to: (1) share research results through the ASHG Annual Meeting and in the American Journal of Human Genetics (AJHG); (2) advance genetic research by advocating for research support; (3) educate current and future genetics professionals, health care providers, advocates, policymakers, educators, students, and the public about all aspects of human genetics; and (4) promote genetic services and support responsible social and scientific policies. For more information about ASHG, please visit our Web site at: <a href="http://www.ashg.org" rel="nofollow">http://www.ashg.org</a>. -------------------------------------------------------------------------------- *Please note that all press registrants will be required to provide appropriate media credentials and identification to ASHG Press Office staff before receiving a press badge to access meeting events. chelsea.scorr on "TKL Research Continues to Strengthen Corporate Excellence" http://biotechbistro.com/forum/topic/tkl-research-continues-to-strengthen-corporate-excellence#post-158 Tue, 26 Jul 2011 14:48:54 +0000 chelsea.scorr 158@http://biotechbistro.com/forum/ FOR IMMEDIATE RELEASE Contact: Kelly Sladek SCORR Marketing 308-237-5567 <a href="mailto:Kelly@scorrmarketing.com">Kelly@scorrmarketing.com</a> TKL Research Continues to Strengthen Corporate Excellence (Rochelle Park, NJ; July 26, 2011) - TKL Research announced today that Kevin Vernarec has assumed the newly created position of Vice President of Operational Excellence. In this new role, Vernarec will carry the responsibility for ensuring that all clinical research organization (CRO) systems and processes are performed with optimum quality and are executed utilizing appropriately allocated resources. Also, he will assure that the best technology is used in the most cost-efficient means possible. “Those who have worked with Kevin appreciate the deep experience and vast knowledge he has brought to TKL with new or improved ways of delivering our services,” said Dr. Bob Reardon, Executive Vice President, COO. “The objective of his role is to ensure client satisfaction and continuous operational improvements resulting in exceptional and increasing business relationships.” Prior to TKL Research, Vernarec held a variety of high-level operations positions for multinational CROs. His breadth of experience covers global project management, clinical operations, proposals, budgeting and costing, CTMS and EDC systems implementation, vendor management, process re-engineering and project planning and tracking. Kevin holds a Bachelor of Science degree in biology from Pennsylvania State University. About TKL Research Headquartered in Rochelle Park, New Jersey, TKL Research is a full-service international clinical research organization (CRO) serving the pharmaceutical, biotechnology, medical device and consumer healthcare industries. TKL Research provides comprehensive clinical trial management services for Phase I-IV clinical research studies, including an inpatient Phase I facility and outpatient specialized research clinics while delivering to our clients a competitive edge with accelerated enrollment. ### chelsea.scorr on "ICON Acquires Firecrest Clinical" http://biotechbistro.com/forum/topic/icon-acquires-firecrest-clinical#post-151 Thu, 14 Jul 2011 10:35:05 +0000 chelsea.scorr 151@http://biotechbistro.com/forum/ ICON Acquires Firecrest Clinical Acquisition Enables ICON to Enhance Investigator Site Performance & Quality Dublin, Ireland, July 14th, 2011 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the acquisition of Firecrest Clinical, a market-leading provider of technology solutions that boost investigator site performance and study management. Founded in 2001 and headquartered in Limerick, Ireland, Firecrest Clinical provides a comprehensive site performance management system that has been used by 9 of the world’s top-10 pharma companies to improve compliance, consistency and execution of activities at investigative sites. The web-based solution enables accurate study information, including protocol information, training manuals and case report forms, to be rolled out quickly and simultaneously to sites. Site behaviour can then be tracked to ensure training is understood, procedures are being followed, timelines are met and study parameters are maintained. “Delivering consistent, real-time information to sites and a clear path to follow in the conduct of trials not only boosts the quality of trials, it also drives efficiencies and improves study timelines,” commented Peter Gray, CEO at ICON plc. “We have worked with Firecrest on a number of trials and have seen first hand how their technology improves quality through enhanced protocol compliance and drives efficiencies by reducing data queries and errors at sites. Our combined commitment to quality and our shared vision for using innovative technology to deliver more efficient and effective development programs make the companies a good fit.” “We are delighted to be joining ICON at a time when technology is driving transformation within the pharmaceutical and clinical trials industry,” commented Gary Hughes, Firecrest CEO and Co-Founder. “Leveraging ICON’s global presence and deep client relationships will enable us to continue to grow and develop new and innovative technology solutions. We also see real synergies between both companies in terms of technology vision and look forward to combining the expertise from both companies to drive innovation.” -more- About ICON plc ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,800 employees, operating from 77 locations in 39 countries. Further information is available at <a href="http://www.iconplc.com" rel="nofollow">http://www.iconplc.com</a> About Firecrest Firecrest definitively improves clinical site performance through e-clinical technology solutions that provide investigator training and study management tools. Reducing trial costs and protocol deviation, Firecrest is proven to enhance compliance, consistency, and the quality of execution for all study-related procedures and activities. Firecrest works to increase patient recruitment by 10-12 percent and produces much cleaner data with a 40-50 percent reduction in data queries. Further information is available at <a href="http://www.firecrestclinical.com" rel="nofollow">http://www.firecrestclinical.com</a> DISCLOSURE NOTICE: The information contained in this release is as of July 14, 2011. ICON assumes no obligation to update forward-looking statements contained in this release. A description of risks and uncertainties relating to ICON and its business can be found in ICON’s Annual Report and Form 20-F for the fiscal year ended December 31, 2010 and in its Reports of Foreign Issuer on Form 6-K filed with the US Securities and Exchange Commission. ICON/ICLR-F Contacts Sam Farthing VP Investor Relations ICON plc + 353-1-291-2000 Rosie Allan Weber Shandwick +44 (0)20 7067 0190 chelsea.scorr on "VINCE & ASSOCIATES CLINICAL RESEARCH OPENS NEUROPSYCHIATRIC RESEARCH CENTER" http://biotechbistro.com/forum/topic/vince-amp-associates-clinical-research-opens-neuropsychiatric-research-center#post-150 Thu, 14 Jul 2011 08:36:43 +0000 chelsea.scorr 150@http://biotechbistro.com/forum/ FOR IMMEDIATE RELEASE CONTACT: Bruce Copeland Vince & Associates Clinical Research Office: 913.696.1601 Email: <a href="mailto:bcopeland@vinceandassociates.com">bcopeland@vinceandassociates.com</a> VINCE & ASSOCIATES CLINICAL RESEARCH OPENS DEDICATED NEUROPSYCHIATRIC RESEARCH CENTER Overland Park, KS July 14, 2011– Vince & Associates Clinical Research, a leading provider of early development clinical trials to the global biopharmaceutical industry announces the opening of their new, dedicated Neuropsychiatric Research Center in Overland Park, KS. This research facility supports the needs of the pharmaceutical and biotechnology sectors by providing effective study recruitment, medical management and oversight in study volunteers across a range of neuropsychiatric disorders including both acute and chronic schizophrenia. “While Vince and Associates has been conducting clinical trials in schizophrenia over the past decade, this dedicated unit will allow us to better serve the needs of both study volunteers and our biopharmaceutical clients,” said Dr. Brad Vince, President and Medical Director. Debra Kelsh, MD, a Board-Certified Psychiatrist and an Investigator in over 300 clinical trials, will serve as Medical Director of the new Neuropsychiatric Research Center. “The safety and security of our study volunteers was highly emphasized during the design of the unit,” said Dr. Kelsh. Successful subject recruitment at Vince & Associates is driven by the extensive and proprietary database in excess of 40,000 verified patients and healthy normal volunteers. By conducting an in-depth medical history, Vince and Associates helps ensure an accurate estimate of study volunteers available for clinical trials. Full-time recruitment staff, a community outreach team and an in-house call center establishes a strong foundation in subject recruitment and routinely positions Vince and Associates as a top enrolling research facility. About Vince & Associates Clinical Research Vince & Associates Clinical Research has been providing clinical research services to the biopharmaceutical industry for more than a decade. The research professionals at Vince & Associates are proud to be recognized in the industry as a “Center of Research Excellence.” Vince & Associates has become a premier clinical research site by utilizing The Physician Research ModelSM of operation where study teams are led by highly experienced Principal Investigators intricately involved in all aspects of the clinical trial process. Vince & Associates also recently opened a new state-of-the-art, multi-million dollar, 90 bed Clinical Pharmacology Unit which combines the ultimate in subject safety and luxury. This boutique hotel-like facility features 10 unique and luxuriously designed research suites. Bedside 20 inch touch-screen entertainment systems allow study volunteers individual access to watch TV and movies, surf the net or play video games. This new unit has the upscale amenities necessary for the recruitment and retention of study volunteers in both short and long term clinical trials. From the safety and security of the controlled access unit to the added features of a movie theatre and game rooms, no detail has been overlooked. More Information If you would like additional information on this topic, please contact Bruce Copeland at 913.696.1601 or <a href="mailto:bcopeland@vinceandassociates.com">bcopeland@vinceandassociates.com</a> or review our website at <a href="http://www.vinceandassociates.com" rel="nofollow">http://www.vinceandassociates.com</a>. ### biotechprog on "New Biotechnology Progress Award with $3K Honorarium" http://biotechbistro.com/forum/topic/new-biotechnology-progress-award-with-3k-honorarium#post-140 Tue, 21 Jun 2011 15:55:35 +0000 biotechprog 140@http://biotechbistro.com/forum/ Deadline for new Biotechnology Progress award: July 15, 2011 Don’t miss out on your chance to earn a $3,000 honorarium. For more information on The Biotechnology Progress Award for Excellence in Biological Engineering see <a href="http://bit.ly/l1kfWL" rel="nofollow">http://bit.ly/l1kfWL</a>. Read the press release at <a href="http://bit.ly/j9TZSK" rel="nofollow">http://bit.ly/j9TZSK</a>. Biotechnology Progress, published by Wiley-Blackwell, is an official publication of the American Institute of Chemical Engineers and its technological community, the Society for Biological Engineering. pjbosc on "ISCO Launches New Marketing Campaign for Lifeline" http://biotechbistro.com/forum/topic/isco-launches-new-marketing-campaign-for-lifeline#post-117 Thu, 12 May 2011 14:13:52 +0000 pjbosc 117@http://biotechbistro.com/forum/ International Stem Cell Corporation (OTCBB: ISCO) today announced the Company's near-term marketing plans for products manufactured by its Lifeline Skin Care™ (Lifeline) subsidiary. Following the highly successful launch in late 2010 of Lifeline's first two products with sales that greatly exceeded expectations, Lifeline has now commenced a new phase in the marketing plan for its skin care products. The first step in these initiatives is a series of briefings being conducted in New York City this week with editors at beauty magazines whose readership reflects the target user base for Lifeline's anti-aging skin care products. This will be followed by a series of targeted email offerings developed by Lifeline's marketing partner, The Mauldin Companies, culminating in a larger offering in June. Lifeline's anti-aging products were developed by ISCO's scientific research team in collaboration with internationally recognized cosmetic experts. The first two products, a Day Serum and a Night Serum, both contain an extract from ISCO's proprietary human parthenogenetic stem cells which, in combination with vitamin complexes, provides major rejuvenating effects, including improvement in skin tone and elasticity, and improvement in the appearance of fine lines and wrinkles. These effects have been substantiated by clinical studies performed at industry-leading independent testing organizations. Lifeline's premium product line includes the Recovery Night Moisture Serum and the Defensive Day Moisture Serum/SPF-15. These products are most commonly ordered together in a 2-pack, and can be purchased by visiting Lifeline's website atwww.lifelineskincare.com. The products are also available at selected luxury spas and physician's offices in the United States. Dr. Ruslan Semechkin, President and CEO of Lifeline Skin Care, added that Lifeline plans to launch additional skin care products later this year, including an eye cream formulated with a proprietary stem cell derivative and a cleanser. Lifeline is focusing its marketing on direct-to-consumer channels to highly targeted audiences with traditional print and media promotions planned for later in the year. The Company's goal is to generate favorable word-of-mouth through a network of satisfied customers, thereby building a community of users based on their shared experience of success with Lifeline's proprietary anti-aging products. Ken Aldrich, Co-founder and Chairman of Lifeline's parent company, International Stem Cell Corporation, said, "The success of Lifeline Skin Care demonstrates that we can make a positive difference in people's lives today, while also providing an important source of revenue to support ISCO's development of stem cell therapies that may in the future result in treatment for many widespread human diseases." About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at <a href="http://www.internationalstemcell.com" rel="nofollow">http://www.internationalstemcell.com</a>. To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. Forward-looking Statements Statements pertaining to anticipated developments, product introduction and marketing plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements. pjbosc on "A Message From International Stem Cell Corporation CEO Kenneth Aldrich Regarding" http://biotechbistro.com/forum/topic/a-message-from-international-stem-cell-corporation-ceo-kenneth-aldrich-regarding#post-116 Wed, 11 May 2011 21:56:02 +0000 pjbosc 116@http://biotechbistro.com/forum/ I've had a lot of calls and emails asking me about the impact of currently ongoing clinical trials by Geron and Advanced Cell Technology. We at International Stem Cell Corporation are delighted to see companies entering clinical trials with pluripotent stem cells. The success of all companies in our field aids ISCO as well and each new disease or injury that scientists demonstrate to be treatable with stem cells represents another potential market for our pluripotent stem cells in the future." Kenneth Aldrich - CEO of International Stem Cell Corporation pjbosc on "International Stem Cell Corporation Receives Approvals Toward..." http://biotechbistro.com/forum/topic/international-stem-cell-corporation-receives-approvals-toward#post-91 Wed, 09 Mar 2011 11:43:31 +0000 pjbosc 91@http://biotechbistro.com/forum/ International Stem Cell Corporation Receives Important Approvals Towards Creating New Parthenogenetic Stem Cell Lines in the United States International Stem Cell Corporation (OTCBB:ISCO), <a href="http://www.internationalstemcell.com" rel="nofollow">http://www.internationalstemcell.com</a>, announced today the achievement of a major milestone in its efforts to establish a bank of immune-matched parthenogenetic stem cells in the United States by receiving the statutory approvals required to move forward with the next phase of its stem cell banking program. An independent Stem Cell Research Oversight (SCRO) committee approved ISCO's program to obtain human oocytes (eggs) in California. The independent SCRO committee is responsible for reviewing the scientific rationale, ethics and compliance with State and Federal regulations and guidelines for studies involving human stem cells. This approval in combination with the earlier reported Institutional Review Board (IRB) clearance with regard to medical safety opens the way for ISCO's stem cell banking program to begin registering clinical investigators. ISCO's study is designed to produce new clinical-grade human parthenogenetic stem cell lines that can be immune matched to millions of individuals for use in the emerging field of regenerative medicine. ISCO's breakthrough discoveries have resulted in unique stem cells carrying distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic" stem cells (hpSCs). Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals. Currently ISCO has a collection of ten hpSC lines that are shared with collaborators and used for research purposes. Although these ten stem cell lines conform to all relevant US standards, they were derived outside the United States. New cell lines created under this study will be ISCO's first hpSC to be produced in the United States. ISCO's scientists, leaders the field of creating therapeutic cells from hpSC, will work with these lines targeting new treatments for human diseases. The company will also share these cells with other scientists to further clinical research. ISCO intends to derive and store these cells at its Oceanside facilities, which are designed to create cells suitable for clinical use. Simon Craw, PhD, says, "These approvals, combined with our technology, make the establishment of a bank of immune matched stem cells practical and allow for the possibility of cell-based therapy to be economic for millions of people. We believe we are one of the first commercial entities in the United States to have progressed to this point." ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB): International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, <a href="http://www.internationalstemcell.com" rel="nofollow">http://www.internationalstemcell.com</a> To subscribe to receive ongoing corporate communications please click on the following link: <a href="http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0" rel="nofollow">http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0</a>. FORWARD-LOOKING STATEMENTS Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and therapies, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. Key Words: Stem Cells, Biotechnology, Parthenogenesis International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 <a href="mailto:kaldrich@intlstemcell.com">kaldrich@intlstemcell.com</a> Or Simon Craw, PhD, Vice President 760-940-6383 <a href="mailto:sc@intlstemcell.com">sc@intlstemcell.com</a> pjbosc on "International Stem Cell Corporation - Peer Reviewed Publications" http://biotechbistro.com/forum/topic/international-stem-cell-corporation-peer-reviewed-publications#post-74 Tue, 25 Jan 2011 15:56:06 +0000 pjbosc 74@http://biotechbistro.com/forum/ International Stem Cell's Scientists in Collaboration with World Leading Stem Cell Experts Extend Understanding of Human Parthenogenetic Stem Cells in Peer Reviewed Publications International Stem Cell Corporation (OTCBB:ISCO), <a href="http://www.internationalstemcell.com" rel="nofollow">http://www.internationalstemcell.com</a>, in collaboration with leading stem cell scientists, announces findings that human parthenogenetic stem cells (hpSC) and human embryonic stem cells (hESC) are similar in their undifferentiated state, and are capable of differentiating into neural lineages such as functional retinal pigment epithelial (RPE) cells that have potential to treat retinal diseases such as age-related macular degeneration. ISCO's CEO Andrey Semechkin, Ph.D., said: "These data are extremely important as they demonstrate that parthenogenetic stem cells have therapeutic potential like conventional embryonic stem cells; however, parthenogenetic stem cells have the additional benefit of superior immune-matching capabilities." This evidence is presented in a recently published paper entitled: "Equivalence of conventionally-derived and parthenote-derived human embryonic stem cells" published in PLoS ONE (Public Library of Science). Hans Keirstead, Ph.D., Professor of Anatomy and Neurobiology and Neurological Surgery at the University of California, Irvine and the senior author of the paper, said: "This work is the first wide-ranging comparison between these two important pluripotent stem cell types and demonstrates that human parthenogenetic stem cells are capable of differentiation along retinal lineages." According to Nikolay Turovets, Ph.D., ISCO's Director of Research and Therapeutic Development and co-author of the paper, "Derivation of RPE from hpSC is the next logical step on the way to developing patient-specific therapies to treat eye degenerative disorders. If studies using RPE derived from hESC demonstrate utility in treating such diseases, it may become necessary to address problems associated with immune rejection. RPE derived from hpSC can be better immune-matched to the patient, thus reducing the chance of immune rejection." This work forms part of ISCO's ophthalmology program developed in collaboration with the team of scientists at the University of California, Irvine led by Dr. H. Keirstead. One of the principal aims of the program is to create three-dimensional retinal tissue for transplantation that may be used to rescue the vision of individuals with retinitis pigmentosa, a group of inherited disorders characterized by progressive vision loss. ISCO has established collaborations with other leading stem cell researchers to exploit the unique qualities of hpSCs. In addition to the collaboration with Keirstead, ISCO scientists co-authored a publication with Jeanne Loring, Ph.D., the Director of the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla, entitled "Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture" published in Cell Stem Cell in January, 2011. Ruslan Semechkin, Ph.D., Vice President of ISCO and co-author on this paper, said: "We are excited about being involved in Dr. Loring's work, which compares molecular characteristics of hundreds of different human pluripotent cell lines." Dr. Loring added: "hpSCs are intriguing because they are pluripotent like hESCs, but have differences in imprinting, the process in embryonic development in which certain genes are inactivated. This makes hpSCs tremendously valuable for understanding the molecular basis of the imprinting process in humans." ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB): International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, <a href="http://www.internationalstemcell.com" rel="nofollow">http://www.internationalstemcell.com</a>. To subscribe to receive ongoing corporate communications please click on the following link: <a href="http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0" rel="nofollow">http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0</a>. FORWARD-LOOKING STATEMENTS Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. Key Words: Stem Cells, Biotechnology, Parthenogenesis International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 <a href="mailto:kaldrich@intlstemcell.com">kaldrich@intlstemcell.com</a> or Jeffrey Janus, Senior VP 760-940-6383 <a href="mailto:jjanus@intlstemcell.com">jjanus@intlstemcell.com</a> pjbosc on "International Stem Cell Corporation Announces $25 Million Common Stock Financing" http://biotechbistro.com/forum/topic/international-stem-cell-corporation-announces-25-million-common-stock-financing#post-67 Tue, 14 Dec 2010 16:07:52 +0000 pjbosc 67@http://biotechbistro.com/forum/ International Stem Cell Corporation (OTCBB:ISCO),www.internationalstemcell.com, announced today that it had entered into an agreement with Aspire Capital Fund, LLC, to provide, at the Company's sole option, up to $25 million of equity capital over the next three years. As part of this transaction, Aspire purchased, upon execution of the agreement, 333,333 shares of ISCO Common Stock at a price of $1.50 per share, a 7% premium over Friday's closing price of $1.40 per share. Pricing of future sales under the agreement will be determined each time the Company elects to sell shares to Aspire by a formula that is based on the actual sale prices of the Company's stock over the 12 days preceding each sale to Aspire. Thus, the Company will control the timing and amount of any sales of its Common Stock to Aspire, and will always know at the time it gives a notice of sale what the cost of that round of financing will be. Aspire has no right to require any sales by the Company, but is obligated to make purchases as the Company directs in accordance with the purchase agreement, and the Company has the right to terminate the agreement at any time. The agreement does not restrict other financings by the Company. A more detailed description of the transaction agreements with Aspire is set forth in the Company's current report on Form 8-K, filed today with the U.S. Securities and Exchange Commission. Ray Wood, Chief Financial Officer of ISCO, commented on the agreement, "This transaction is designed to provide both a source of working capital and maximum flexibility for the Company in determining the pricing and timing of any future financing it elects to use under this agreement. It provides us with access to capital that we believe will be adequate to fund our research activities for an extended period of time, but does not preclude us from pursuing additional financing during the term of the agreement. Because of the pricing flexibility this facility gives us, we believe that this agreement will provide both the lowest cost of capital currently available, plus maximum flexibility in meeting our future financing needs. If we don't need working capital or don't need as much as expected, we may elect not to use the facility. If we do need capital, it is available and we can choose when to obtain it." ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB) International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent humanstem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryosand, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed and is now marketing a line of skin care products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, <a href="http://www.internationalstemcell.com" rel="nofollow">http://www.internationalstemcell.com</a>. To subscribe to receive ongoing corporate communications please click on the following link: <a href="http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0" rel="nofollow">http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0</a>. ABOUT ASPIRE CAPITAL FUND, LLC Aspire Capital Fund, LLC is an institutional investor based in Chicago,Illinois, with a fundamental investment approach. Aspire Capital invests in a wide range of companies and industries emphasizing life sciences, energy and technology. FORWARD-LOOKING STATEMENTS Statements pertaining to financing plans and capital needs, anticipatedtechnological developments and therapeutic applications, the potential benefits of opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. Key Words: Stem Cells, Biotechnology, Parthenogenesis International Stem Cell Corporation Kenneth C. Aldrich, Chairman, 760-940-6383 <a href="mailto:kaldrich@intlstemcell.com">kaldrich@intlstemcell.com</a> or Ray Wood, CFO, 760-640-6383 <a href="mailto:rwood@intlstemcell.com">rwood@intlstemcell.com</a> dperrino on "Attending BIO in Atlanta?" http://biotechbistro.com/forum/topic/attending-bio-in-atlanta#post-17 Fri, 03 Apr 2009 13:34:40 +0000 dperrino 17@http://biotechbistro.com/forum/ Great networking opportunity during BIO in Atlanta. Please come to the Biotechnology Institute's Biotech Education Banquet, Sunday 5/17. Attended by leading Biotech execs, BIO and Institute Board Members, and educators from around the globe. $250 per seat, $2500 per table (10 seats). Contact <a href="mailto:dperrino@biotechinstitute.org">dperrino@biotechinstitute.org</a> for more info and discounts, or register at <a href="http://www.biotechinstitute.org/banquet" rel="nofollow">http://www.biotechinstitute.org/banquet</a> by May 1. dperrino on "Attending BIO?" http://biotechbistro.com/forum/topic/attending-bio#post-16 Fri, 03 Apr 2009 13:33:21 +0000 dperrino 16@http://biotechbistro.com/forum/ Great networking opportunity during BIO in Atlanta. Please come to the Biotechnology Institute's Biotech Education Banquet, Sunday 5/17. Attended by leading Biotech execs, BIO and Institute Board Members, and educators from around the globe. $250 per seat, $2500 per table (10 seats). Contact <a href="mailto:dperrino@biotechinstitute.org">dperrino@biotechinstitute.org</a> for more info and discounts, or register at <a href="http://www.biotechinstitute.org/banquet" rel="nofollow">http://www.biotechinstitute.org/banquet</a> by May 1. laravmarks on "BioPharma sentiment takes a plunge" http://biotechbistro.com/forum/topic/biopharma-sentiment-takes-a-plunge#post-12 Wed, 04 Mar 2009 06:52:14 +0000 laravmarks 12@http://biotechbistro.com/forum/ Silico Research has released the findings of its annual survey of sentiment in the biopharma industry. As might be expected sentiment has taken a major turn for the worse with a net 38% of respondents seeing the prospects for the industry as declining over the next year. In 2008 a net 30% saw the prospects for the industry improving over the next year. This year a net 62% of respondents reported that the prospects for the industry are currently worse than this time last year. The state of capital markets was the most often cited reason for the decline in sentiment in the industry. The decline in sentiment was particularly pronounced in English speaking countries and the biotechnology sector. The survey was conducted during February 2009 and 103 senior executives in the industry took part in the survey. However, the capital crunch means that alliances with larger companies are more vital than ever with a net 64% of respondents viewing alliances as more important to their organisation in 2009 compared to 2008. For more information about the survey please email <a href="mailto:Lara@silico-research.com">Lara@silico-research.com</a> Silico Research is a research consultancy that is a trusted advisor to leading organisations on partnering, alliances, relationships and reputation management both within the organisation and externally. What sets Silico Research apart is the evidence-based nature of its analysis. Quantitative and qualitative research of the highest quality using customised survey and focus groups are the core of Silico Research’s products and services. Silico's clients come from a wide range of public and private sectors, including the life sciences, healthcare, technology, energy and telecommunication.